These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 10907616)

  • 1. TCAs or SSRIs as initial therapy for depression?
    Tyra JM; Greenawald MH
    J Fam Pract; 1999 Nov; 48(11):845-6. PubMed ID: 10907616
    [No Abstract]   [Full Text] [Related]  

  • 2. Study addresses question of preferred initial therapy for depression.
    Am J Health Syst Pharm; 1996 Sep; 53(17):1994. PubMed ID: 8870882
    [No Abstract]   [Full Text] [Related]  

  • 3. SSRI or tricyclics for depression?
    Bushell I; Newton W
    J Fam Pract; 1996 Oct; 43(4):345-6. PubMed ID: 8874367
    [No Abstract]   [Full Text] [Related]  

  • 4. TCAs vs SSRIs. Same bang for whose buck?
    Gallo JJ
    Arch Fam Med; 1999; 8(4):326-7. PubMed ID: 10418539
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.
    Serrano-Blanco A; Gabarron E; Garcia-Bayo I; Soler-Vila M; Caramés E; Peñarrubia-Maria MT; Pinto-Meza A; Haro JM;
    J Affect Disord; 2006 Apr; 91(2-3):153-63. PubMed ID: 16458976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of TCAs and SSRIs in the treatment of major depression in hospitalized geriatric patients.
    Miller FT; Freilicher J
    J Geriatr Psychiatry Neurol; 1995 Jul; 8(3):173-6. PubMed ID: 7576042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
    Serrano-Blanco A; Suárez D; Pinto-Meza A; Peñarrubia MT; Haro JM;
    J Eval Clin Pract; 2009 Feb; 15(1):195-203. PubMed ID: 19239602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?
    Levitt AJ; Joffe RT; Kamil R; McIntyre R
    J Clin Psychiatry; 1999 Sep; 60(9):613-6. PubMed ID: 10520980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial.
    Simon GE; Heiligenstein J; Revicki D; VonKorff M; Katon WJ; Ludman E; Grothaus L; Wagner E
    Arch Fam Med; 1999; 8(4):319-25. PubMed ID: 10418538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.
    Simon GE; VonKorff M; Heiligenstein JH; Revicki DA; Grothaus L; Katon W; Wagner EH
    JAMA; 1996 Jun; 275(24):1897-902. PubMed ID: 8648870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
    Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
    J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.
    Anderson IM
    Depress Anxiety; 1998; 7 Suppl 1():11-7. PubMed ID: 9597346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SSRIs vs tricyclic antidepressants.
    Griffin GH
    J Fam Pract; 1996 Feb; 42(2):110. PubMed ID: 8606296
    [No Abstract]   [Full Text] [Related]  

  • 15. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
    Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influences on cost effectiveness.
    Patel V
    Br J Psychiatry; 1996 Sep; 169(3):381. PubMed ID: 8879730
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of depression in patients maintained on dialysis.
    Finkelstein FO; Watnick S; Finkelstein SH; Wuerth D
    J Psychosom Res; 2002 Oct; 53(4):957-60. PubMed ID: 12377309
    [No Abstract]   [Full Text] [Related]  

  • 18. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression.
    McGrath PJ; Stewart JW; Janal MN; Petkova E; Quitkin FM; Klein DF
    Am J Psychiatry; 2000 Mar; 157(3):344-50. PubMed ID: 10698808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
    Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
    Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation strategies with serotonergic-noradrenergic combinations.
    Nelson JC
    J Clin Psychiatry; 1998; 59 Suppl 5():65-8; discussion 69. PubMed ID: 9635550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.